Publications

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in neurological emergencies from the perspective of a US hospital. Abstract EE579, ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in cardiac surgery from the perspective of a US hospital. Abstract EE734, ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in acute hypertension from the perspective of a US hospital. Abstract EE125, ISPOR EU 2023.

Bean K, Miller B, Jensen I, Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547, ISPOR EU 2023.

Miller B, Russel-Szymczyk M, Jensen I, Shah A, Alexopoulos T, Herbert A, et al. Cost-consequence of cladribine tablets for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in the UK. Abstract EE658, ISPOR EU 2023.

Yoshino T, Hooda N, Younan D, Shitara K, Heinemann V,…, Suh M, Reichert H, et al. A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. Abstract 127P, European Society for Medical Oncology (ESMO) Asia Congress. Ann Oncol 34(Sup 4):S1519; doi: 10.1016/j.annonc.2023.10.262. Singapore, December 2023.

Davies S, Boller E, Beaubrun A, Miller C, Jensen I. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV Plus for the diagnosis of viral respiratory infections from a US health plan perspective. Abstract ID309, AMP 2023 Annual Meeting & Expo, Salt Lake City, UT, November 2023.

Franklin M, Emden MR, Bauer E, Nguyen AT, Sacks N, Kawamatsu S, Kawano Y,  Mitrani-Gold FS, et al. Prevalence of acute uncomplicated cystitis in Japan. Poster presentation, IDWeek, Boston, MA, October 2023.

Franklin M, Emden MR, Kautz S, Nguyen AT, Sacks NC, Ju S, Mitrani-Gold FS, Joshi AV, Preib MT. Cost burden of patients with oral antibiotic treatment failure for uncomplicated urinary tract infection in the United States. Poster presentation, IDWeek, Boston, MA, October 2023.

Nelson CB, Jiang X, Suh M, Fryzek J. Prevention of respiratory syncytial virus hospitalizations (RSVH) in US infants who paid through Medicaid would have a greater benefit for Black, Hispanic, Asian/Pacific Islander, Native American and Other race/ethnicity infants, and have a substantial impact on overall RSVH burden and related costs: Rates of respiratory syncytial virus hospitalization (RSVH) among US infants by race/ethnicity and insurance payer, NIS 2018-2020. Poster 1536169, IDWeek 2023, Boston, MA, October 2023.